ORYZON to participate in three scientific meetings on CNS

MADRID, SPAIN and CAMBRIDGE MA.

• 10th Clinical Trials on Alzheimer's Disease (CTAD-2017)

• SfN’s 47TH annual meeting (Neuroscience 2017)

• CNS-Summit 2017

Oryzon Genomics (ISIN Code: ES0167733015, ORY), a public clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced today that it will participate this month of November in three specialized conferences in the CNS domain: the 10th Clinical Trials on Alzheimer's Disease (CTAD-2017), the SfN’s 47th annual meeting (Neuroscience 2017) and the CNS-Summit 2017.

Click here to see the full Press Release